Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin: a review
AUTOR(ES)
Andrade, Luis Jesuíno de Oliveira, Atta, Ajax Mercês, D'Almeida Junior, Argemiro, Paraná, Raymundo
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2008-04
RESUMO
Hepatitis C (HCV) is now the main cause of chronic hepatic disease, cirrhosis and hepatocellular carcinoma. Several extrahepatic diseases have been associated with chronic HCV infection, and in most cases appear to be directly related to the viral infection. Thyroid disorders are common in patients with chronic HCV. Some patients with chronic hepatitis C experience thyroid problems, and thyroid dysfunction may also be a side effect of interferon-based treatment. The principal risk factor for developing thyroid disease in the course of antiviral therapy is the previous positivity for anti-thyroid antibodies (anti-thyroid peroxidase) especially in older women. Screening for autoantibodies and serum thyroid-stimulating hormone is recommended before, during and after interferon-alpha treatment, and patients should be informed of the risk of thyroid dysfunction. This review includes a summary of thyroid disease associated with chronic HCV infection, interferon-alpha and ribavirin for treatment of HCV and potential to induce thyroid dysfunction.
Documentos Relacionados
- Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
- Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
- Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
- Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment.
- Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C